Surgery Partners’ second quarter results were received positively by the market, with management highlighting that revenue and adjusted EBITDA came in ahead of expectations. CEO Eric Evans credited growth in higher-acuity surgical procedures—particularly in orthopedics, vascular, and spine—as a primary driver, despite overall surgical case volumes remaining flat. Management also pointed to the company’s ongoing focus on recruiting new physicians and maintaining strong relationships with clinical partners as factors supporting same-facility revenue growth. Additionally, a shift in payer mix toward more government reimbursement was anticipated and reflected in operating margin trends, which management described as an expected outcome of the evolving business mix.
Is now the time to buy SGRY? Find out in our full research report (it’s free for active Edge members).
Surgery Partners (SGRY) Q2 CY2026 Highlights:
- Revenue: $848.9 million vs analyst estimates of $830.7 million (2.7% year-on-year growth, 2.2% beat)
- Adjusted EPS: $0.10 vs analyst estimates of $0.06 (59.6% beat)
- Adjusted EBITDA: $125.2 million vs analyst estimates of $123.6 million (14.7% margin, 1.3% beat)
- The company reconfirmed its revenue guidance for the full year of $3.4 billion at the midpoint
- EBITDA guidance for the full year is $530 million at the midpoint, in line with analyst expectations
- Operating Margin: 12%, down from 13.5% in the same quarter last year
- Sales Volumes were flat year on year (3.4% in the same quarter last year)
- Market Capitalization: $1.95 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Surgery Partners’s Q2 Earnings Call
-
Brian Tanquilut (Jefferies) asked about trends in broader surgical volumes and the sustainability of high-acuity procedure growth. CEO Eric Evans responded that while total case numbers are flat, high-acuity volumes continue to rise and are in line with expectations.
-
Joanna Gajuk (Bank of America) probed the impact of payer mix dynamics and the flow of procedures into ambulatory centers as Medicare regulations evolve. COO Justin Oppenheimer explained that the payer mix shift was most pronounced in surgical hospitals and that new, more complex cases are increasingly being performed in ASCs.
-
Matthew Gillmor (KeyBanc) questioned the Idaho Falls transaction structure and its implications for the company’s future financial profile. CFO David Doherty clarified that the sale includes all related operations in the market and will significantly reduce debt and capital requirements.
-
Sarah James (Cantor Fitzgerald) asked whether commercial payer mix pressures were linked to physician turnover and if trends had stabilized. CEO Eric Evans stated that mix challenges from last year are moderating and that the underlying commercial position remains strong.
-
Albert Rice (UBS) inquired about the cadence and scale of future acquisitions. Evans confirmed that while M&A activity was light in the first half due to the Idaho Falls focus, the pipeline remains robust and the long-term strategy for consolidation is unchanged.
Catalysts in Upcoming Quarters
In the coming quarters, the StockStory team will be watching (1) the closing and subsequent financial impact of the Idaho Falls divestiture and management’s update to full-year guidance, (2) the pace and quality of new physician recruitment and integration, and (3) execution on new ambulatory facility development and selective M&A. Progress on cost control and payer mix management will also be important signals for operating leverage.
Surgery Partners currently trades at $15.02, down from $15.53 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).
The Best Stocks for High-Quality Investors
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.
